159 related articles for article (PubMed ID: 28938439)
1. Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
Brønden A; Albér A; Rohde U; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2017 Nov; 102(11):4153-4162. PubMed ID: 28938439
[TBL] [Abstract][Full Text] [Related]
2. The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.
Brønden A; Albér A; Rohde U; Gasbjerg LS; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Feb; 20(2):362-369. PubMed ID: 28786523
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses.
Rohde U; Sonne DP; Christensen M; Hansen M; Brønden A; Toräng S; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2016 May; 101(5):2076-83. PubMed ID: 27003305
[TBL] [Abstract][Full Text] [Related]
4. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.
Brønden A; Mikkelsen K; Sonne DP; Hansen M; Våben C; Gabe MN; Rosenkilde M; Tremaroli V; Wu H; Bäckhed F; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Jul; 20(7):1623-1631. PubMed ID: 29493868
[TBL] [Abstract][Full Text] [Related]
5. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2016 Jun; 18(6):571-80. PubMed ID: 26888164
[TBL] [Abstract][Full Text] [Related]
6. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
7. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Rohde U
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
[TBL] [Abstract][Full Text] [Related]
8. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
Xie C; Iroga P; Bound MJ; Grivell J; Huang W; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetologia; 2024 Jul; 67(7):1260-1270. PubMed ID: 38561463
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs.
Rehfeld JF; Knop FK; Asmar A; Madsbad S; Holst JJ; Asmar M
Scand J Gastroenterol; 2018 Dec; 53(12):1429-1432. PubMed ID: 30449207
[TBL] [Abstract][Full Text] [Related]
10. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
[TBL] [Abstract][Full Text] [Related]
11. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
Zander M; Taskiran M; Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 2001 Apr; 24(4):720-5. PubMed ID: 11315837
[TBL] [Abstract][Full Text] [Related]
12. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
Dalsgaard NB; Gasbjerg LS; Hansen LS; Hansen NL; Stensen S; Hartmann B; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2021 Mar; 184(3):383-394. PubMed ID: 33449919
[TBL] [Abstract][Full Text] [Related]
13. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
14. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.
Bahne E; Sun EWL; Young RL; Hansen M; Sonne DP; Hansen JS; Rohde U; Liou AP; Jackson ML; de Fontgalland D; Rabbitt P; Hollington P; Sposato L; Due S; Wattchow DA; Rehfeld JF; Holst JJ; Keating DJ; Vilsbøll T; Knop FK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518693
[TBL] [Abstract][Full Text] [Related]
15. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
Keller J; Trautmann ME; Haber H; Tham LS; Hunt T; Mace K; Linnebjerg H
Regul Pept; 2012 Nov; 179(1-3):77-83. PubMed ID: 22960288
[TBL] [Abstract][Full Text] [Related]
16. Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.
Shaddinger BC; Young MA; Billiard J; Collins DA; Hussaini A; Nino A
J Clin Pharmacol; 2017 Oct; 57(10):1322-1329. PubMed ID: 28543352
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
Borg MJ; Bound M; Grivell J; Sun Z; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetes Obes Metab; 2019 Mar; 21(3):640-647. PubMed ID: 30370686
[TBL] [Abstract][Full Text] [Related]
18. Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling.
Gether IM; Bahne E; Nerild HH; Rehfeld JF; Hartmann B; Holst JJ; Vilsbøll T; Sonne DP; Knop FK
Eur J Endocrinol; 2024 Mar; 190(4):314-326. PubMed ID: 38551029
[TBL] [Abstract][Full Text] [Related]
19. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin.
Bahne E; Hansen M; Brønden A; Sonne DP; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2016 Oct; 18(10):955-61. PubMed ID: 27265206
[TBL] [Abstract][Full Text] [Related]
20. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
